Analyzing the Financial Health of Adaptimmune Therapeutics plc (ADAP)

Publicly-traded company Adaptimmune Therapeutics plc (NASDAQ:ADAP) had a closing price of $0.92 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $5.25, this means that the stock is underpriced by 82.48%. In the past 52 weeks the company’s stock price has moved within the range of $0.83 to $8.04.

This particular stock’s 5-day moving average is 0.99, its 20-day moving average is 0.98 and its 100-day moving average is 2.12. Adaptimmune Therapeutics plc (ADAP) currently has 96.35M shares outstanding, which means that its market capitalization is $88.65M.

The Details: Adaptimmune Therapeutics plc (ADAP) Financial Health

We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Adaptimmune Therapeutics plc Return on Assets is -36.30%.

What Does Wall Street Say about Company?

When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for ADAP is Overweight. Out of 7 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 4 rated it hold, and 3 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for Adaptimmune Therapeutics plc (ADAP) was a Overweight – from a survey of 8 analysts. Of the analysts who provided ratings, 3 rated the company a Hold, 0 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 5 rated it a Buy.

Understanding Profitability at Adaptimmune Therapeutics plc (ADAP)

A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Adaptimmune Therapeutics plc, for the quarter ending on 09/2019, the company posted EPS of -0.33. The average estimate of Wall Street analysts had projected -0.28.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.31, compared to 0.06 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 5 analysts is 1.48M – compared to 40.79M posted in the year-ago period.